155 related articles for article (PubMed ID: 29795240)
1. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
[No Abstract] [Full Text] [Related]
2. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.
Lakshman A; Ravi P; Rajkumar SV; Kumar SK
Leukemia; 2018 Sep; 32(9):2083-2085. PubMed ID: 29802327
[No Abstract] [Full Text] [Related]
3. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
[No Abstract] [Full Text] [Related]
4. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
8. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
9. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
11. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
12. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
[TBL] [Abstract][Full Text] [Related]
13. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
[No Abstract] [Full Text] [Related]
14. Timing of treatment of smoldering myeloma: early treatment.
Mateos MV; González-Calle V
Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
[TBL] [Abstract][Full Text] [Related]
15. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
[No Abstract] [Full Text] [Related]
16. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
[TBL] [Abstract][Full Text] [Related]
17. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
[TBL] [Abstract][Full Text] [Related]
18. How I approach smoldering multiple myeloma.
Vaxman I; Gertz MA
Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
[TBL] [Abstract][Full Text] [Related]
19. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
